Form D · Pharmaceuticals

Amytrx Therapeutics, Inc.

Nashville, TN · CIK 0001649024

Offering snapshot reported Jan 31, 2024 · SEC filing

Reported sold
$725K
Offering amount: $6M
Investors reported
7
Form D · investor count
Minimum accepted
$50K
Reported outside-investor minimum
First sale
Dec 15, 2023
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jan 31, 2024Initial$725,000No comparison7SEC filing
Aug 12, 2020Initial$3,590,000No comparison34SEC filing
Sep 5, 2017Initial$0No comparison0SEC filing
Jul 1, 2016Amendment$600,000$0vs Dec 16, 20157SEC filing
Dec 16, 2015Amendment$600,000$550,000vs Aug 4, 20157SEC filing
Aug 4, 2015Initial$50,000No comparison1SEC filing

Offering details

Securities
Debt, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-504045

Source: Form D, filed Jan 31, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Thomas Andrews Director
Daniel Canale Director
Dennis Carlo Director
Matthew Gonda Director
Larry Greer Director
Lawrence Greer Director
Jack J Hawiger Director
Michael Howell Director
Satish Joshi Director
Jerry M Kluft Director
Robert E Mc Neilly Director
Daniel Pirtle Director
Raymond Pirtle Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
40 Burton Hills Boulevard Suite 200
Nashville, TN, 37215